Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 1 Surgery 1 Sarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Ductal Adenocarcinoma 1 Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer 1 Multiple Myeloma 1 Medulloblastoma 1 Lung Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 HER2-positive Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms 1 Breast Cancer Invasive 1

Interventions

Specimen Handling 6 Magnetic Resonance Spectroscopy 6 Biopsy 6 Doxorubicin 5 pembrolizumab 4 X-Rays 4 Phantoms, Imaging 4 Nuclear Medicine Department, Hospital 4 Cyclophosphamide 4 liposomal doxorubicin 3 fludarabine 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 selpercatinib 2 palbociclib 2 larotrectinib 2 ivosidenib 2 fludarabine phosphate 2 ensartinib 2 atezolizumab 2 anlotinib 2 Temozolomide 2 Radiation 2 Irinotecan 2 Ifosfamide 2 Carboplatin 2 Bevacizumab 2 trifluridine tipiracil drug combination 1 trastuzumab deruxtecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × Neoadjuvant Therapy × 30 days × Clear all

NCT07612098 2026-05-28

SPARE-04

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡